The Company was founded in 1988 by Dr. Massimo Porro on the basis of his pioneering activity in the design and industrial development of CRM 197-based glycoconjugate vaccines for the prevention of bacterial meningitis in infants and young children due to Gram-negative and Gram-positive encapsulated bacteria. Some of these glycoconjugate vaccines, which involved the non-toxic mutant diphtheria protein CRM197 covalently linked to capsular polysaccharides and oligosaccharides derived from the capsule of Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae, are now manufactured and marketed in USA and Europe by two major vaccine producers.
The Company’s commercial strategy is that of Licensing third Parties with its proprietary know-how, protected by a technological body of several International Patents, including USA and Europe, relative to the molecular entities designed and developed as vaccines for diseases having broad impact in the public health. The Licensing strategy includes the Technology Transfer of the production processes and the technical assistance for implementing the large-scale production processes.
Several cooperations have been implemented in the past more than two decades with the most renowned Companies of the western world producing vaccines for human use. Since the year 2008, a new broad cooperation has been opened in the territory of the P.R. of China for producing polyvalent meningococcal and pneumococcal glycoconjugate vaccines with a modern technology but at an affordable price for the paediatric population of that country.